Live Chat

Vir Biotechnology 거래 VIR

매도
 매수

VirBiotechnology 실시간 차트

5m 15m 30m 1h 4h 1d 1w

상품 기초

Weekly Search
Weekly
Daily
날짜 종료 변경 변동(%) 열기 높음 낮음

최신 뉴스

Tommy Yap 2025 Feb 22, 16:00

Week Ahead: Australia Inflation and US Core PCE Price Index in Focus

Forex Indices
Why did stock market drop today due to Walmart's economic outlook.
Vanessa L 2025 Feb 21, 06:40

Why Did Stock Market Drop Today? Walmart’s Forecast Sparks Economic Concerns

Frances Wang 2025 Feb 20, 16:00

Shiba inu news: What is happening to Shiba Inu today?

Cryptocurrencies
Alvaro Ramos 2025 Feb 20, 16:00

Dow jones stock markets today: Dow falls 450 points

Indices
Frances Wang 2025 Feb 20, 16:00

Lucid stock news today: Is Lucid stock expected to go up?

Stocks
Frances Wang 2025 Feb 20, 16:00

Forex market update: US Dollar struggles on mixed data

Forex
Tommy Yap 2025 Feb 20, 16:00

Morning Note: Oil Prices Climb, UK Retail Sales Rise & U.S. PMI

Morning Note Oil
Space.Xia 2025 Feb 20, 16:00

Asian Markets Stagnate on Trade Fears; Alibaba Drives HK Surge

정보

스프레드

0.07

스프레드(%)

0.7330 %

레버리지

1:10

익일 이자 매수

-0.0597 %

익일 이자 매도

-0.0292 %

통화

USD

거래 시간

시장 폐장

월요일

14:31 - 20:59

화요일

14:31-20:59

수요일

14:31-20:59

목요일

14:31-20:59

금요일

14:31-20:59

분석 및 통계

열기

---

이전 종가

---

52주 최고/최저

--- – ---

시가총액

1317980416

발행 주식 수

137720000

수익 날짜 (다음)

0000-00-00

배당수익률

배당락일

예상 연간 배당금

0

예상 연간 배당수익률

0

EPS

-3.93

이 상품에 대해 자세히 알아보기

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

관련 상품

자산
매도
매수
변동(%)

지금 거래하기

지금 거래하기

지금 거래하기

지금 거래하기
view_all_instruments
Trustpilot
Live Chat